Quantcast

Latest hyperphosphatemia Stories

2010-05-06 07:00:00

NEW YORK, May 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of its short-term Phase 3 study of Zerenex(TM) (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. The initiation of this study marks the commencement of the Company's Phase 3 registration program for Zerenex, which is being conducted...

2010-04-15 07:30:00

NEW YORK, April 15 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported updated long-term efficacy and safety data on Zerenex(TM) (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) from an open-label extension study in patients with end-stage renal disease (ESRD) who are on dialysis. This data was presented yesterday at the National Kidney Foundation (NKF) 2010 Spring Clinical...

2010-04-13 07:30:00

NEW YORK, April 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that several posters on Zerenex(TM) (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease who are on dialysis, have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010, in Orlando, Florida....

2010-02-02 07:30:00

NEW YORK, Feb 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 12th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on Tuesday, February 9, 2010 at 2:00pm EST. A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An...

2010-01-15 17:54:57

Colon cleansing is used widely for colonoscopic exploration and colonic and gynecological surgery. Oral sodium phosphate (OSP) solution is the osmotic laxative most commonly used for this purpose. It is known that OSP can induce severe hyperphosphatemia and hypocalcemia due to excessive absorption of phosphates, and there have been reports of deaths and irreversible dialysis-requiring renal insufficiency. However, no prospective studies have investigated the prevalence of hyperphosphatemia in...

2010-01-07 10:52:00

NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 28th Annual Healthcare Conference in San Francisco, CA on Thursday, January 14, 2010 at 7:30 am PST. A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast...

2010-01-05 07:30:00

NEW YORK, Jan. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical program for Zerenex(TM) (ferric citrate), its iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD). The SPA provides agreement...

2009-11-24 07:30:00

NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being held in New York City. Mr. Bentsur's presentation will be webcast live on Wednesday, December 2nd at 10:30AM ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived...

2009-11-06 07:30:00

NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference...

2009-11-04 07:30:00

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit being held in New York City. Mr. Bentsur's presentation will be webcast live on Tuesday, November 10th at 3:40 pm ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'